Jun 29th 2012 - Edison Investment Research today published a report on wilex entitled "Doubling PF Survival". In summary, the report says:
The new data on HER2 negative breast cancer reinforces the 2010 positive findings in pancreatic cancer. In the sub-group of 95 patients who had received prior adjuvant chemotherapy, Mesupron plus Xeloda (capecitabine) gave 8.3 month progression free survival vs 4.3 months on capecitabine alone. Although not statistically powered, this is a positive trend. Together, these results could allow partnering by mid 2013 and the development of a Phase II/III programme, probably in the adjuvant setting. Data from the ARISER Rencarex study is due Q412.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
